Početna › Multipli mijelom › North Carolina › Durham
Kliničke studije za Multipli mijelom u gradu Durham, NC
37 studija za Multipli mijelom traži sudionike na lokacijama u gradu Durham i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
U tijeku regrutacijaFaza 3
- Research Site, Chapel Hill · 10 mi udaljenosti
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
U tijeku regrutacijaFaza 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi udaljenosti
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
U tijeku regrutacijaFaza 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
U tijeku regrutacijaFaza 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi udaljenosti
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
U tijeku regrutacijaFaza 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi udaljenosti
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
U tijeku regrutacijaFaza 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi udaljenosti
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
U tijeku regrutacijaFaza 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi udaljenosti
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
U tijeku regrutacijaFaza 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi udaljenosti
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
U tijeku regrutacijaFaza 1/2
- GSK Investigational Site, Chapel Hill · 10 mi udaljenosti
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
U tijeku regrutacijaFaza 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
U tijeku regrutacijaFaza 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi udaljenosti
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
U tijeku regrutacija
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi udaljenosti
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
U tijeku regrutacijaFaza 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi udaljenosti
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
U tijeku regrutacijaFaza 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi udaljenosti
Selinexor and Backbone Treatments of Multiple Myeloma Patients
U tijeku regrutacijaFaza 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi udaljenosti
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
U tijeku regrutacijaFaza 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi udaljenosti
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
U tijeku regrutacijaFaza 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi udaljenosti
Registry of Older Patients With Cancer
U tijeku regrutacijaOpažajna studija
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi udaljenosti
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
U tijeku regrutacijaFaza 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
U tijeku regrutacijaFaza 2
- University of North Carolina, Chapel Hill · 10 mi udaljenosti
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
U tijeku regrutacijaFaza 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi udaljenosti
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi udaljenosti
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
U tijeku regrutacijaFaza 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi udaljenosti
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
U tijeku regrutacijaFaza 1
- University of North Carolina, Chapel Hill · 10 mi udaljenosti
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
U tijeku regrutacijaFaza 1
- University of North Carolina, Chapel Hill · 10 mi udaljenosti
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
U tijeku regrutacijaFaza 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi udaljenosti
Registry for Adults With Plasma Cell Disorders (PCD's)
U tijeku regrutacijaOpažajna studija
- North Carolina Cancer Hospital, Chapel Hill · 10 mi udaljenosti
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
U tijeku regrutacijaOpažajna studija
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi udaljenosti
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Duke University Health System (DUHS), Durham
Studije za Multipli mijelom u drugim gradovima
- New York City, NY60 studija
- Boston, MA42 studija
- Atlanta, GA41 studija
- Houston, TX38 studija
- Nashville, TN32 studija
- Denver, CO27 studija
- Rochester, MN24 studija
- St. Louis, MO24 studija
- Columbus, OH24 studija
- Baldwin Park, CA23 studija
- Chicago, IL22 studija
- Seattle, WA22 studija
Ostale studije u gradu Durham
- Rak dojke63 studija
- Rak (sve vrste)58 studija
- Nemikrocelularni karcinom pluća39 studija
- Metastatski karcinom33 studija
- Akutna mijeloična leukemija33 studija
- Rak pluća32 studija
- Rak prostate32 studija
- Kolorektalni rak28 studija
- Kronična limfocitna leukemija27 studija
- Rak jajnika27 studija
- Srčano zatajenje26 studija
- Rak gušterače24 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.